Prevalence of HBV, HCV, HIV, Sexually Transmitted Infections, and Their Complications

A special issue of Epidemiologia (ISSN 2673-3986).

Deadline for manuscript submissions: closed (31 December 2023) | Viewed by 2003

Special Issue Editor

Unit of Infectious Diseases, Department of Medicine, Surgery, and Pharmacy, University of Sassari, 07100 Sassari, Italy
Interests: hepatology; HIV; antimicrobial stewardship; antivirals; infectious diseases during pregnancy; penitentiary medicine
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

As it is well known, HIV, with testing and treatment, has a viral suppression of 95%–95%–95%, respectively; therefore, reducing viral hepatitis is essential as a primary global threat.

The World Health Organization (WHO) estimates that more than 1 million Sexually Transmitted Diseases (STDs) are acquired daily. Every year, there are about 357 million new STDs. Furthermore, STDs increase the risk of HIV infection up to three-fold or more. The availability of quick diagnostic tests, POCTs, test-and-treat strategies, and interventional programs on targeted subpopulations seem to be the future for blood-borne viruses and STDs.

This Special Issue aims to include papers on HBV, HCV, HIV, Sexually Transmitted Infections, and their complications in order to propose new diagnostics, therapeutical, and control strategies in this field.

Dr. Vito Fiore
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Epidemiologia is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • viral hepatitis
  • HIV
  • HCV
  • sexually transmitted diseases
  • long-term infections complications
  • innovation in STDs diagnostics
  • STDs treatment

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

7 pages, 534 KiB  
Opinion
The COVID-19 Pandemic Affected Hepatitis C Virus Circulation and Genotypic Frequencies—Implications for Hepatitis C Prevention, Treatment and Research
by Julio Daimar Oliveira Correa and José Artur Bogo Chies
Epidemiologia 2024, 5(2), 160-166; https://doi.org/10.3390/epidemiologia5020011 - 4 Apr 2024
Cited by 1 | Viewed by 1622
Abstract
Hepatitis C is regarded as a global health issue caused by hepatitis C virus (HCV) infection. HCV is targeted for elimination by 2030 as a global public health goal. However, the COVID-19 pandemic has changed human circulation and prevented access to diagnostics and [...] Read more.
Hepatitis C is regarded as a global health issue caused by hepatitis C virus (HCV) infection. HCV is targeted for elimination by 2030 as a global public health goal. However, the COVID-19 pandemic has changed human circulation and prevented access to diagnostics and treatment to many other diseases, including hepatitis C. COVID-19 impacted HCV global elimination efforts with implications not fully comprehended yet. The high genetic variability in HCV makes the development of vaccines and pan-genotypic drug therapies a difficult task. Changes in the dynamics of HCV impose new challenges for public health and opportunities for future research. Meta-analysis, the follow up of new cases and sampling of HCV patients compared with previously available data are options for investigating the possible changes. The determination of HCV genotypes and subtypes is important for understanding viral dynamics and treatment; therefore, the changes in genotype and subtype prevalences can directly affect such processes. Recent results in the literature already suggest changes in HCV dynamics during the COVID-19 pandemic, both considering viral circulation and differential genotypic frequencies in distinct geographic areas. In this context, we propose a further examination of these trends using different approaches to provide support for the hypothesis that the COVID-19 pandemic affected HCV circulation, since these findings would have important implications for hepatitis C prevention, treatment and research. Full article
Show Figures

Figure 1

Back to TopTop